| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029318 |
| Receipt No. | R000031511 |
| Official scientific title of the study | Safety evaluation of a short-term infusion of ramucirumab for GI tract cancer patients |
| Date of disclosure of the study information | 2017/09/28 |
| Last modified on | 2018/03/28 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Safety evaluation of a short-term infusion of ramucirumab for GI tract cancer patients | |
| Title of the study (Brief title) | Safety evaluation of a short-term infusion of ramucirumab | |
| Region |
|
|
| Condition | ||||
| Condition | Gastric and colorectal cancer | |||
| Classification by specialty |
|
|||
| Classification by malignancy | Malignancy | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To evaluate the safety of a short-term infusion of ramucirumab |
| Basic objectives2 | Safety |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Incidence of infusion related reaction (any grade) at the first short-term infusion |
| Key secondary outcomes | Incidence of infusion related reaction (any grade) at any time
Incidence of adverse events (grade3 or more) except for infusion related reaction Duration of ramucirumab treatment |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | To administer ramucirumab in a short period of time | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Gastric or colorectal cancer patients who had undergone ramucirumab and are supposed to continue ramucirumab treatment | |||
| Key exclusion criteria | 1. Severe respiratory or cardiovascular diseases
2. Need for dose reduction of ramucirumab 3. Past history of infusion related reaction (grade3 or more) due to chemotherapeutic agents 4. Past history of infusion related reaction (any grade) due to ramucirumab 5. Daily use of antiallergic agents or steroids due to allergic diseases 6. Inadequate conditions, as diagnoses by the primary physician |
|||
| Target sample size | 42 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroya Taniguchi |
| Organization | Aichi Cancer Center Hospital |
| Division name | the Department of Clinical Oncology |
| Address | 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan |
| TEL | 052-762-6111 |
| h.taniguchi@aichi-cc.jp | |
| Public contact | |
| Name of contact person | Seiichiro Mitani |
| Organization | Aichi Cancer Center Hospital |
| Division name | the Department of Clinical Oncology |
| Address | 1-1 Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan |
| TEL | 052-762-6111 |
| Homepage URL | |
| smitani@aichi-cc.jp | |
| Sponsor | |
| Institute | Aichi Cancer Center Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Aichi Cancer Center Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Local Government |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 愛知県がんセンター中央病院(愛知県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031511 |